That the effects of hypoxia and HIF-1α on therapy resistance and survival at least in part is in cross-talk with EGFR opens for new application of established EGFR-inhibitors as well as for emerging HIF-inhibitors combined with strategies to minimize tumor hypoxia. This evidence concerns the gene HIF1A and neoplasm.